Streetbeat News

ARTV

Artiva Biotherapeutics Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

10.30

Mkt cap

249M

Volume

5.6K

High

10.30

P/E Ratio

-4.14

52-wk high

17.31

Low

10.25

Div yield

N/A

52-wk low

9.68

Artiva Biotherapeutics has released its third quarter 2024 financial results and announced the expansion of its Board of Directors with Dr. Alison Moore, who brings expertise in cell therapy and manufacturing. This move aims to advance their AlloNK® platform in autoimmune diseases.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) will participate in a fireside chat at the Jefferies London Healthcare Conference on November 20, 2024. This participation may provide insights into the company's strategies and developments in cell therapies for autoimmune diseases and cancers.

Portfolio Pulse from

November 11, 2024 | 9:30 pm

Needham analyst Gil Blum has reiterated a Buy rating on Artiva Biotherapeutics (NASDAQ:ARTV) and maintained a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 3:58 pm

Artiva Biotherapeutics reported a significant increase in quarterly losses, with Q2 EPS at $(22.00), a 56.14% decrease from $(14.09) in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 8:14 pm

Artiva Biotherapeutics (NASDAQ:ARTV) recently priced its IPO at $12.00 per share, raising approximately $167 million. The company focuses on developing cell therapies for autoimmune diseases and cancers, with its lead program, AlloNK, currently in clinical trials. Needham and Wedbush have initiated coverage with bullish ratings and price targets of $23 and $18, respectively. Initial clinical results for AlloNK in lupus are expected in the first half of 2025.

Portfolio Pulse from Vandana Singh

August 13, 2024 | 6:14 pm

Needham analyst Gil Blum has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 1:42 pm

Wedbush analyst David Nierengarten has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with an Outperform rating and a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:45 pm

Cantor Fitzgerald has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with an Overweight rating and a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:26 am

TD Cowen has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating, as announced by analyst Tyler Van Buren.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:23 am

Jefferies analyst Kelly Shi has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and set a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:41 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.